Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day

Journal of Diabetes and its Complications

Volumn 28, Issue 5, 2014, Pages 735-741

  Ahrén, Bo ^a   Vorokhobina, Natalia ^b   Souhami, Elisabeth ^c   Demil, Nacima ^c   Ye, Jenny ^d   Aronson, Ronnie ^e  

^a LUND UNIVERSITY   (Sweden)

^b NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

^c SANOFI   (France)

^d Biostatistics and Programming   (United States)

^e LMC DIABETES AND ENDOCRINOLOGY   (Canada)

Author keywords

Flexibility; Glycaemic control; Lixisenatide; Self monitored plasma glucose; Type 2 diabetes mellitus

Indexed keywords

AMYLASE; CALCITONIN; GLUCOSE; HEMOGLOBIN A1C; LIXISENATIDE; METFORMIN; TRIACYLGLYCEROL LIPASE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PEPTIDE; ZP10A PEPTIDE;

ADULT; AGED; AMYLASE BLOOD LEVEL; ARTICLE; ASTHMA; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CALCITONIN BLOOD LEVEL; CONTROLLED STUDY; DIABETES TREATMENT SATISFACTION QUESTIONNAIRE STATUS; DIET RESTRICTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEAL; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; URTICARIA; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; METABOLISM; MIDDLE AGED; POSTPRANDIAL STATE; TIME;

AGED; BLOOD GLUCOSE; BREAKFAST; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEALS; MIDDLE AGED; PEPTIDES; POSTPRANDIAL PERIOD; TIME FACTORS; TREATMENT OUTCOME;

EID: 84906794531     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2014.05.012     Document Type: Article

References (21)

1. American Diabetes Association Diagnosis and classification of diabetes mellitus Diabetes Care 36 Suppl. 1 2013 S67 S74
2. A.J. Garber, M.J. Abrahamson, J.I. Barzilay, L. Blonde, Z.T. Bloomgarden, and M.A. Bush et al. American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive summary Endocrine Practice 19 2013 536 557
3. L. Monnier, C. Colette, R. Rabasa-Lhoret, H. Lapinski, C. Caubel, and A. Avignon et al. Morning hyperglycaemic excursions: A constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes Diabetes Care 25 2002 737 741
4. P.N. Bavenholm, J. Pigon, C.G. Ostenson, and S. Efendic Insulin sensitivity of suppression of endogenous glucose production is the single most important determinant of glucose tolerance Diabetes 50 2001 1449 1454
5. G. Boden, X. Chen, and J.L. Urbain Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production Diabetes 45 1996 1044 1050
6. S. Franc, D. Dardari, C. Peschard, J.P. Riveline, M. Biedzinski, and B. Boucherie et al. Can postprandial blood glucose excursion be predicted in type 2 diabetes? Diabetes Care 33 2010 1913 1918
7. M.A. Powers, R.M. Cuddihy, D. Wesley, and B. Morgan Continuous glucose monitoring reveals different glycaemic responses of moderate- vs high-carbohydrate lunch meals in people with type 2 diabetes Journal of the American Dietetic Association 110 2010 1912 1915
8. M. Christensen, F.K. Knop, T. Vilsboll, and J.J. Holst Lixisenatide for type 2 diabetes mellitus Expert Opinion on Investigational Drugs 20 2011 549 557
9. M. Lorenz, C. Pfeiffer, A. Steinsträsser, R.H. Becker, H. Rütten, and P. Ruus et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes - Relationship to postprandial glycaemia Regulatory Peptides 185 2013 1 8
10. B. Ahrén, D.A. Leguizamo, P. Miossec, S. Saubadu, and R. Aronson Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M) Diabetes Care 36 2013 2543 2550
11. G.B. Bolli, M. Munteanu, S. Dotsenko, E. Niemoeller, G. Boka, and Y. Wu et al. Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1) Diabetic Medicine 2013 10.1111/dme.12328 (Epub ahead of print)
12. V.A. Fonseca, R. Alvarado-Ruiz, D. Raccah, G. Boka, P. Miossec, and J.E. Gerich et al. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono) Diabetes Care 35 2012 1225 1231
13. M. Pinget, R. Goldenberg, E. Niemoeller, I. Muehlen-Bartmer, H. Guo, and R. Aronson Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P) Diabetes, Obesity & Metabolism 15 2013 1000 1007
14. M.C. Riddle, R. Aronson, P. Home, M. Marre, E. Niemoeller, and P. Miossec et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L) Diabetes Care 36 2013 2489 2496
15. M.C. Riddle, T. Forst, R. Aronson, L. Sauque-Reyna, E. Souhami, and L. Silvestre et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1) Diabetes Care 36 2013 2497 2503
16. J. Rosenstock, D. Raccah, L. Koranyi, L. Maffei, G. Boka, and P. Miossec et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X) Diabetes Care 36 2013 2945 2951
17. Y. Seino, K.W. Min, E. Niemoeller, and A. Takami Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulphonylurea (GetGoal-L-Asia) Diabetes, Obesity & Metabolism 14 2012 910 917
18. C. Bradley The Diabetes Treatment Satisfaction Questionnaire: DSTQ C. Bradeley, Handbook of psychology and diabetes: A guide to psychological measurement in diabetes research and practice 1994 Harwood Academic Publishers 111 132
19. M. Davies, and J. Speight Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus Diabetes, Obesity & Metabolism 14 2012 882 892
20. M. Peyrot, A.H. Barnett, L.F. Meneghini, and P.M. Schumm-Draeger Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study Diabetes, Obesity & Metabolism 14 2012 1081 1087
21. M.J. Davies, J.J. Gagliardino, L.J. Gray, K. Khunti, V. Mohan, and R. Hughes Real-world factors affecting adherence to insulin therapy in patients with type 1 or type 2 diabetes mellitus: A systematic review Diabetic Medicine 30 2013 512 524